Second, we could not show the precise strategy for treating NASH by targeting lipid absorption; however, we are currently assessing the influence of genetic or pharmacological alteration of CD36 and MTP expression in rats on the absorption of PA and development of NASH. Here, CD36 is linked to metabolic dysfunction-associated steatohepatitis.